4-羟基-alpha1-[[[6-(3-苯基丙氧基)己基]氨基]甲基]-1,3-苯二甲醇 | 94749-11-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-羟基-alpha1-[[[6-(3-苯基丙氧基)己基]氨基]甲基]-1,3-苯二甲醇
• 中文别名: 沙美特罗杂质C
• 英文名称: 4-Hydroxy-α1-[[[6-(3-phenylpropoxy)hexyl]amino]methyl]-1,3-benzenedimethanol
• 英文别名: Des(phenylbutoxy)phenylpropoxy salmeterol；2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(3-phenylpropoxy)hexylamino]ethyl]phenol
• CAS: 94749-11-8
• 化学式: C₂₄H₃₅NO₄
• 分子量: 401.546
• InChiKey: PCSOCURVSKRIIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  29
• 可旋转键数：
  15
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  82
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  1,3-苯二甲醇, ALPHA1-(氨基甲基)-4-羟基- 生成 4-羟基-alpha1-[[[6-(3-苯基丙氧基)己基]氨基]甲基]-1,3-苯二甲醇
  参考文献：
  名称：

  SKIDMORE, IAN FREDERICK;LUNTS, LAWRENCE HENRY CHARLES;FINCH, HARRY;NAYLOR+

  摘要：

  DOI：

文献信息

• Phenethanolamine derivatives
  申请人：Glaxo Group Ltd.

  公开号：US04992474A1

  公开（公告）日：1991-02-12

  Phenethanolamine derivatives are disclosed of formula ##STR1## wherein m is 2 to 8; n is 1 to 7 provided that m+n is 4 to 12; Ar is phenyl or phenyl substituted by one or two halogen atoms, alkyl or alkoxy groups or by an alkylenedioxy group; R.sup.1 and R.sup.2 are hydrogen or alkyl provided that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and the physiologically acceptable salts and solvates thereof. The compounds have a selective stimulant action at .beta..sub.2 -adrenoreceptors and may be used inter alia in the treatment of diseases associated with reversible airways obstructions such as asthma and chronic bronchitis. The compounds may be formulated in conventional manner as pharmaceutical compositions with physiologically acceptable carriers or excipients. The compounds may be prepared, for example by alkylation of an amine: ##STR2## where R.sup.3, R.sup.5 and R.sup.6 is hydrogen or a protecting group, followed by removal of any protecting group.

  本发明公开了公式##STR1##的苯乙醇胺衍生物，其中m为2至8；n为1至7，前提是m+n为4至12；Ar为苯基或被一个或两个卤素原子、烷基或烷氧基或烷二氧基基团取代的苯基；R.sup.1和R.sup.2为氢或烷基，前提是R.sup.1和R.sup.2中碳原子的总和不超过4；以及其生理上可接受的盐和溶剂化物。这些化合物在β2-肾上腺素能受体上具有选择性的刺激作用，可用于治疗与可逆性气道阻塞相关的疾病，如哮喘和慢性支气管炎等。这些化合物可以与生理上可接受的载体或赋形剂一起按照传统方法制成药物组合物。这些化合物可以通过烷基化胺的方法制备，例如：##STR2##其中R.sup.3、R.sup.5和R.sup.6为氢或保护基，随后去除任何保护基。
• Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
  申请人：Robinson B. Cynthia

  公开号：US20050026884A1

  公开（公告）日：2005-02-03

  A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a β2-agonist bronchodilator for the treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease.

  一种药物或兽药组合物，包含选自脱氢表雄酮和/或硫酸脱氢表雄酮或其盐的第一种活性剂，以及包含β2-激动剂支气管扩张剂的第二种活性剂，用于治疗哮喘、慢性阻塞性肺病或任何其他呼吸道疾病。该组合物以各种配方和试剂盒的形式提供。本专利的产品适用于哮喘、慢性阻塞性肺病或任何其他呼吸道疾病的预防和治疗。
• SKIDMORE, IAN FREDERICK;LUNTS, LAWRENCE HENRY CHARLES;FINCH, HARRY;NAYLOR+
  作者：SKIDMORE, IAN FREDERICK、LUNTS, LAWRENCE HENRY CHARLES、FINCH, HARRY、NAYLOR+

  DOI：——

  日期：——
• COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A BETA-AGONIST BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  申请人：Epigenesis Pharmaceuticals LLC

  公开号：EP1651168A2

  公开（公告）日：2006-05-03
• EP1651168A4
  申请人：——

  公开号：EP1651168A4

  公开（公告）日：2009-04-01